How I treat thrombotic thrombocytopenic purpura
https://doi.org/10.35754/0234-5730-2025-70-1-128-137
Abstract
Introduction. Thrombotic thrombocytopenic purpura (TTP) is a rare disease manifested by non-immune thrombocytopenia, microangiopathic hemolytic anemia and organ and system dysfunction.
Aim: to present the scheme of treatment of a patient with TTP.
Main findings. The case report of a 32-years-old patient, in whom TTP manifested with anemia, thrombocytopenia, and ischemic stroke, is presented. The patient was successfully treated with plasma exchange, prednisolone, caplacizumab, rituximab. Diagnostic errors, logic of prescription and cancellation of these or those drugs are discussed.
Keywords
Supporting agencies: the study had no sponsorship.
About the Authors
G. M. Galstyan
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Gennadiy M. Galstyan, Dr. Sci. (Med.), Head of the Resuscitation and Intensive Care Department
125167, Moscow
E. E. Klebanova
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Elizaveta E. Klebanova, Physician of the Resuscitation and Intensive Care Department
125167, Moscow
S. Yu. Mamleeva
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Svetlana Yu. Mamleeva, Head of the Express-Laboratory, of the Resuscitation and Intensive Care Department
125167, Moscow
References
1. Scully M., Cataland S., Coppo P., et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. DOI: 10.1111/jth.13571.
2. Roose E., Tersteeg C., Demeersseman R., et al. Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of PregnancyOnset Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open. 2018;02(01):e8–15. DOI: 10.1055/s-0037-1615252.
3. Mariotte E., Azoulay E., Galicier L., et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237–45. DOI: 10.1016/S2352-3026(16)30018-7.
4. Amorosi E.L., Ultman J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(3):139–59.
5. Yamada Y., Ohbe H., Yasunaga H., et al. Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A nationwide Inpatient Database Analysis. Blood. 2019;134(Suppl 1):2374. DOI: 10.1182/blood-2019-125170.
6. Galstyan G.M., Klebanova E.E., Mamleeva S.Yu., et al. Neurological disorders in patients with thrombotic thrombocytopenic purpura. Klinicheskaya meditsina. 2023;101(1):41–9 (In Russian). DOI: 10.30629/0023-2149-2023-101-1-41-49.
7. Zhang X.-H., Liang H.-M. Systematic review with network meta-analysis. Diagnostic values of ultrasonography, computed tomography, and magnetic resonance imaging in patients with ischemic stroke. Medicine. 2019;98(30):e16360. DOI: 10.1097/md.0000000000016360.
8. Matsumoto M., Fujimura Y., Wada H., et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. International journal of hematology. 2017;106(1):3–15. DOI: 10.1007/S12185-017-2264-7.
9. Galstyan G.M., Klebanova E.E., Mamleeva S.Yu., et al. Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura — diagnostic difficulties and errors. Gematologiya i transfuziologiya. 2023;68(3):317–334 (In Russian). DOI: 10.35754/0234-5730-2023-68-3-317-334.
10. Alwan F., Vendramin C., Vanhoorelbeke K., et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466–71. DOI: 10.1182/BLOOD-2016-12-758656.
11. Benhamou Y., Boelle P.Y., Baudin B., et al. Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the French thrombotic microangiopathies reference center. J Thromb Haemost. 2015;13(2):293–302. DOI: 10.1111/jth.12790.
12. Wahla A.S., Ruiz J., Noureddine N., et al. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. European journal of haematology. 2008;81(4):311–6. DOI: 10.1111/J.1600-0609.2008.01112.X.
13. Moiseev I.S., Rzepecki P., Bogardt J., et al. Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation. 2018; DOI: 10.1038/s41409-018-0374-3.
14. Yu K., Yan M. A Case of Thrombotic Thrombocytopenic Purpura without Pathognomonic Schistocytes.pdf. Clin Pract. 2021;11:223–7. DOI: 10.3390/clinpract11020033.
15. Francis K.K., Kalyanam N., Terrell D.R., et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist. 2007;12(1):11–9. DOI: 10.1634/theoncologist.12-1-11.
16. Benhamou Y., Baudel J.L., Wynckel A., et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. American journal of hematology. 2015;90(6):E127–9. DOI: 10.1002/AJH.23997.
17. Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31. DOI: 10.4161/org.7.1.14027.
18. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):81. DOI: 10.1056/NEJM199108083250604.
19. Knöbl P. Thrombotic thrombocytopenic purpura. Memo. 2018;11(3):220–6. DOI: 10.1007/s12254-018-0429-6.
20. Bell W.R., Ness P.M., Kickler T.S., et al. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403. DOI: 10.1056/NEJM199108083250605.
21. Toyoshige M., Zaitsu Y., Okafuji K., et al. Successful treatment of thrombotic thrombocytopenic purpura with high-dose corticosteroid. Am J Hematol. 1992;41(1):69. DOI: 10.1002/ajh.2830410119.
22. Scully M., Нunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–35. DOI: 10.1111/j.1365-2141.2012.09167.x.
23. Rojnuckarin P., Watanaboonyongcharoen P., Akkawat B., et al. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(5):1148–50. DOI: 10.1111/j.1538-7836.2006.01879.x.
24. Azoulay E., Bauer P.R., Mariotte E., et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019;45(11):1518–39. DOI: 10.1007/s00134-019-05736-5.
25. Scully M., Cataland S.R., Peyvandi F., et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335– 46. DOI: 10.1056/nejmoa1806311.
26. Coppo P., Bubenheim M., Azoulay E., et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733–42. DOI: 10.1182/blood.2020008021.
27. Chen J., Reheman A., Gushiken F.C., et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clini Invest. 2011;121(2):593–603. DOI: 10.1172/JCI41062.
28. Li G.W., Rambally S., Kamboj J., et al. Treatment of refractory thrombotic thrombocytopenic purpura with N -acetylcysteine: a case report. Transfusion. 2014;54(5):1221–4. DOI: 10.1111/trf.12440.
29. Rottenstreich A., Hochberg-Klein S., Rund D., et al. The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2016;41(4):678–83. DOI: 10.1007/s11239-015-1259-6.
30. Coppo P., Cuker A., George J.N. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2018;3(1):26–37. DOI: 10.1002/RTH2.12160.
31. Mazepa M., Masias C., Chaturvedi S. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood. 2019;134(5):415–20.
32. Volker L.A.., Kaufeld J., Miesbach W., et al. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. Blood Adv. 2020;4(13):3093–101. DOI: 10.1182/bloodadvances.2020001987.
33. Cuker A., Cataland S.R., Coppo P., et al. Redefining Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855– 61. DOI: 10.1182/blood.2020009150.
34. Upreti H., Kasmani J., Dane K., et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037– 45. DOI: 10.1182/blood.2019001056.
35. George J.N., Woodson R.D., Kiss J.E., et al. Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders. J Clin Apher. 2006;21:49–56. DOI: 10.1002/jca.20091.
36. Chen H., Fu A., Wang J., et al. Rituximab as fi rst-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253–60. DOI: 10.1177/0300060517695646.
37. McDonald V., Manns K., Mackie I.J., et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. DOI: 10.1111/j.1538-7836.2010.03818.x.
38. Sadler J.E.E. Pathophysiology of Thrombotic Thrombocytopenic Purpura. Blood. 2017;130(10):1181–8. DOI: 10.1182/blood-2017-04-636431.
39. Westwood J.P., Thomas M., Alwan F., et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: Outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–66. DOI: 10.1182/bloodadvances.2017008268.
40. Galstyan G.M., Klebanova E., Mamleeva S., et al. Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura. Semin Thromb Hemost. 2024;18– 21. DOI: 10.1055/s-0044-1791780.
Review
For citations:
Galstyan G.M., Klebanova E.E., Mamleeva S.Yu. How I treat thrombotic thrombocytopenic purpura. Russian journal of hematology and transfusiology. 2025;70(1):128-137. (In Russ.) https://doi.org/10.35754/0234-5730-2025-70-1-128-137
Views:
428
Email this article 
